GE Medical buys service provider, sets up online equipment support
GE Medical Systems announced last week that it has completed its acquisition of OneSource Services. OneSource, founded in 1997, provides clinical services to healthcare facilities’ in-house, multivendor, and OEM service organizations, and has
GE Medical Systems announced last week that it has completed its acquisition of OneSource Services. OneSource, founded in 1997, provides clinical services to healthcare facilities in-house, multivendor, and OEM service organizations, and has particular expertise in laser equipment.
OneSource operations will align with GE Clinical Services, a GE subsidiary headquartered in Brentwood, TN. GE Clinical Services provides comprehensive biomedical service to healthcare providers throughout the U.S.
GEMS also announced a new Internet-based program, Direct Services, to support hospital equipment maintenance and repair. Direct Services offers healthcare providers and third-party providers a Web-based venue to search for and purchase GE and non-GE parts, tubes, and probes online; view service documentation; and access training information.
Other features will be introduced later this year. Customers can view a demonstration of the program at www.mydirectservices.com/ds. The Web site was created for healthcare providers that directly maintain biomedical and imaging equipment.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
